Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flow from operating activities:
Net loss	$ (25,737,634)	$ (19,657,174)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,313,075	1,340,301
Vesting expense	166,312	715,938
Equity instruments issued for management, consulting, and other	356,125	205,193
Amortization of debt discount	0	244,830
Gain on valuation of equity-linked instruments	(115,647)	(164,902)
Benefit from release of valuation allowance	0	(661,658)
Loss on goodwill impairment	7,231,093	2,813,792
Loss on intangible impairment	3,349,375	2,893,548
Loss on long-lived tangible asset impairment	185,469	1,249,727
Loss on fixed asset disposal	14,346	5,858
Changes in assets and liabilities:
Accounts receivable	23,000	(20,769)
Inventories	(42,808)	(98,149)
Prepaid expense and other assets	78,425	(194,363)
Accounts payable	(78,322)	(350,296)
Accrued expenses	869,987	(499,563)
Contract liabilities	41,819	54,548
Other liabilities	(25,415)	(85,790)
Net cash used in operating activities:	(12,370,800)	(12,208,929)
Cash flow from investing activities:
Acquisition of zPREDICTA, net of cash acquired	0	(9,590,214)
Purchase of fixed assets	(419,869)	(910,429)
Acquisition of intangibles	(55,828)	(51,893)
Loan activities	0	(55,000)
Net cash used in investing activities	(475,697)	(10,607,536)
Cash flow from financing activities:
Proceeds from issuance of common stock, net	6,507,050	50,523,527
Proceeds from exercise of warrants into common stock	0	4,513,871
Repayment of debt	0	(4,162,744)
Payment penalties	0	(1,073,470)
Proceeds from issuance of stock pursuant to equity line	236,009	675,590
Repurchase of common stock upon vesting of restricted stock units	(27,654)	(11,526)
Other liabilities	0	(124,500)
Net cash provided by financing activities	6,715,405	50,340,748
Net increase (decrease) in cash and cash equivalents	(6,131,092)	27,524,283
Cash and cash equivalents at beginning of year	28,202,615	678,332
Cash and cash equivalents end of year	22,071,523	28,202,615
Non-cash transactions
Shares issued pursuant to former CEO per agreement related to accrued interest	0	143,573
Increase to operating lease right of use asset and lease liability due to new and modified leases	0	77,128
Inducement shares issued pursuant to convertible debt	0	514,011
Adjustment to fair value	373,303	0
Cash paid during the period for:
Interest paid on debt	$ 3,821	$ 690,508